bioMérieux 将来の成長

ENXTPA:BIM - アナリストの将来予測と過去の財務データ ( )EUR Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	4,562	607	416	906	12
12/31/2025	4,233	536	383	839	13
12/31/2024	3,948	474	420	776	14
6/30/2024	3,807	411	156	495	N/A
3/31/2024	3,741	384	132	470	N/A
12/31/2023	3,675	358	107	445	N/A
9/30/2023	3,688	372	140	459	N/A
6/30/2023	3,701	386	172	472	N/A
3/31/2023	3,645	419	180	474	N/A
12/31/2022	3,589	452	188	475	N/A
9/30/2022	3,525	502	297	583	N/A
6/30/2022	3,460	552	406	690	N/A
3/31/2022	3,418	577	470	757	N/A
12/31/2021	3,376	601	535	825	N/A
9/30/2021	3,296	555	424	716	N/A
6/30/2021	3,216	509	314	608	N/A
3/31/2021	3,167	457	310	595	N/A
12/31/2020	3,118	404	305	583	N/A
9/30/2020	2,997	355	261	538	N/A
6/30/2020	2,876	305	217	493	N/A
3/31/2020	2,775	289	176	451	N/A
12/31/2019	2,675	273	135	408	N/A
9/30/2019	2,601	268	160	419	N/A
6/30/2019	2,527	263	185	431	N/A
3/31/2019	2,474	260	179	415	N/A
12/31/2018	2,421	257	173	400	N/A
9/30/2018	2,372	264	162	370	N/A
6/30/2018	2,323	271	150	340	N/A
3/31/2018	2,306	255	N/A	341	N/A
12/31/2017	2,288	238	N/A	341	N/A
9/30/2017	2,262	216	N/A	340	N/A
6/30/2017	2,237	195	N/A	339	N/A
3/31/2017	2,170	187	N/A	337	N/A
12/31/2016	2,103	179	N/A	336	N/A
9/30/2016	2,068	158	N/A	339	N/A
6/30/2016	2,032	137	N/A	342	N/A
3/31/2016	1,998	124	N/A	326	N/A
12/31/2015	1,965	111	N/A	310	N/A
9/30/2015	1,908	127	N/A	N/A	N/A
6/30/2015	1,851	144	N/A	301	N/A
3/31/2015	1,775	140	N/A	300	N/A
12/31/2014	1,698	135	N/A	298	N/A
9/30/2014	1,656	135	N/A	N/A	N/A
6/30/2014	1,614	135	N/A	246	N/A
3/31/2014	1,601	150	N/A	243	N/A
12/31/2013	1,588	164	N/A	241	N/A

アナリストによる今後の成長予測

収入対貯蓄率: BIMの予測収益成長率 (年間13.6% ) は貯蓄率 ( 1.4% ) を上回っています。

収益対市場: BIMの収益 ( 13.6% ) はFrench市場 ( 12.5% ) よりも速いペースで成長すると予測されています。

高成長収益: BIMの収益は増加すると予測されていますが、大幅には増加しません。

収益対市場: BIMの収益 ( 7.3% ) French市場 ( 5.6% ) よりも速いペースで成長すると予測されています。

高い収益成長: BIMの収益 ( 7.3% ) 20%よりも低い成長が予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: BIMの自己資本利益率は、3年後には低くなると予測されています ( 12.8 %)。

bioMérieux 将来の成長

Future 基準チェック /36

主要情報

今後の成長に関する最新情報

bioMérieux S.A. (EPA:BIM) Just Reported Interim Earnings: Have Analysts Changed Their Mind On The Stock?

bioMérieux S.A. Just Missed Earnings - But Analysts Have Updated Their Models

Price target decreased to €118

Price target increased to €124

Recent updates

Is bioMérieux (EPA:BIM) Using Too Much Debt?

Is There An Opportunity With bioMérieux S.A.'s (EPA:BIM) 31% Undervaluation?

bioMérieux S.A.'s (EPA:BIM) Popularity With Investors Is Under Threat From Overpricing

bioMérieux S.A. (EPA:BIM) Just Reported Interim Earnings: Have Analysts Changed Their Mind On The Stock?

First half 2024 earnings: EPS and revenues exceed analyst expectations

Return Trends At bioMérieux (EPA:BIM) Aren't Appealing

bioMérieux Announces USDA-FSIS Field Service Laboratories Selects GENE-UP Pathogenic E. coli Assay as Primary Method for Shiga Toxin-Producing E. coli Detection

Aurobac Therapeutics, founded by Boehringer Ingelheim, bioMerieux and Evotec, Names Scientific Advisory Board

Upcoming dividend of €0.85 per share

bioMérieux S.A.'s (EPA:BIM) Price In Tune With Earnings

Investors Met With Slowing Returns on Capital At bioMérieux (EPA:BIM)

bioMérieux S.A. to Report First Half, 2024 Results on Sep 05, 2024

Now 21% undervalued

bioMérieux's (EPA:BIM) Conservative Accounting Might Explain Soft Earnings

New minor risk - Earnings quality

Dividend of €0.85 announced

bioMérieux S.A. Just Missed Earnings - But Analysts Have Updated Their Models

These 4 Measures Indicate That bioMérieux (EPA:BIM) Is Using Debt Reasonably Well

Full year 2023 earnings: EPS misses analyst expectations

bioMérieux S.A., Annual General Meeting, May 23, 2024

bioMérieux S.A.'s (EPA:BIM) Price In Tune With Earnings

bioMérieux (EPA:BIM) Has More To Do To Multiply In Value Going Forward

A Look At The Intrinsic Value Of bioMérieux S.A. (EPA:BIM)

These 4 Measures Indicate That bioMérieux (EPA:BIM) Is Using Debt Reasonably Well

bioMérieux (EPA:BIM) Has Some Way To Go To Become A Multi-Bagger

There May Be Reason For Hope In bioMérieux's (EPA:BIM) Disappointing Earnings

Estimating The Intrinsic Value Of bioMérieux S.A. (EPA:BIM)

First half 2023 earnings released: EPS: €1.37 (vs €1.93 in 1H 2022)

Does bioMérieux (EPA:BIM) Have A Healthy Balance Sheet?

Returns At bioMérieux (EPA:BIM) Appear To Be Weighed Down

Upcoming dividend of €0.85 per share at 0.9% yield

Is bioMérieux (EPA:BIM) Using Too Much Debt?

Third quarter 2022 earnings released: EPS: €0.95 (vs €1.37 in 3Q 2021)

The Return Trends At bioMérieux (EPA:BIM) Look Promising

bioMérieux Introduces GENE-UP ENVIROPRO

Do bioMérieux's (EPA:BIM) Earnings Warrant Your Attention?

bioMérieux S.A. to Report Fiscal Year 2022 Results on Mar 08, 2023

bioMérieux (EPA:BIM) Has A Pretty Healthy Balance Sheet

bioMérieux and Jackson Family Wines Introduces Innovation for Wine Quality - BOTTLESAFE™

bioMérieux (EPA:BIM) Ticks All The Boxes When It Comes To Earnings Growth

Is bioMérieux (EPA:BIM) Using Too Much Debt?

Investor sentiment deteriorated over the past week

First half 2022 earnings released: EPS: €1.93 (vs €2.34 in 1H 2021)

Investors Should Be Encouraged By bioMérieux's (EPA:BIM) Returns On Capital

Now 20% undervalued

An Intrinsic Calculation For bioMérieux S.A. (EPA:BIM) Suggests It's 20% Undervalued

Now 22% undervalued

Do bioMérieux's (EPA:BIM) Earnings Warrant Your Attention?

Upcoming dividend of €0.85 per share

bioMérieux's (EPA:BIM) Dividend Will Be Increased To €0.85

bioMérieux Receives Health Canada Approval for BIOFIRE® Blood Culture Identification 2 (BCID2) Panel for Rapid Molecular Bloodstream Infection Identification

bioMérieux Receives Health Canada Approval for BIOFIRE® Blood Culture Identification 2 (BCID2) Panel for Rapid Molecular Bloodstream Infection Identification

Shareholders Would Enjoy A Repeat Of bioMérieux's (EPA:BIM) Recent Growth In Returns

Insufficient new directors

bioMérieux (EPA:BIM) Is Paying Out A Larger Dividend Than Last Year

bioMérieux S.A., Annual General Meeting, May 23, 2022

bioMérieux S.A. (ENXTPA:BIM) entered into an agreement to acquire remaining unknown shares in Specific Diagnostics, LLC for €360 million.

bioMérieux S.A. (ENXTPA:BIM) entered into an agreement to acquire Specific Diagnostics, LLC.

bioMérieux (EPA:BIM) Has Announced That It Will Be Increasing Its Dividend To €0.85

bioMérieux's (EPA:BIM) Dividend Will Be Increased To €0.85

Does bioMérieux (EPA:BIM) Have A Healthy Balance Sheet?

Price target decreased to €118

Full year 2021 earnings: EPS and revenues exceed analyst expectations

I Ran A Stock Scan For Earnings Growth And bioMérieux (EPA:BIM) Passed With Ease

Why We Like The Returns At bioMérieux (EPA:BIM)

Calculating The Intrinsic Value Of bioMérieux S.A. (EPA:BIM)

Price target increased to €124

Here's Why We Think bioMérieux (EPA:BIM) Is Well Worth Watching

Is bioMérieux (EPA:BIM) A Risky Investment?

bioMérieux Achieves First-Ever AOAC INTERNATIONAL Approval for PCR Multiplex Detection of STEC and Salmonella in Cannabis Flower for the GENE-UP® PRO STEC/ Salmonella Assay

Investors Shouldn't Overlook bioMérieux's (EPA:BIM) Impressive Returns On Capital